XENiOS® Will Seek Regulatory Approval for i-lung®
XENiOS®, a commercial-stage medical device company, announced today it expects to receive CE-marking for its i-lung® device within 18 months. XENIOS expects to launch i-lung® in 2017. Currently available devices lack durability and wearability. Additionally, the size of current systems restricts patient mobility and limits quality of life. i-lung represents an innovative and first-of-its-kind fully wearable artificial lung for long-term use in a hospital environment.
"The availability of i-lung will open the door to significant medical progress for respiratory support. For many patients in lung failure currently undergoing invasive mechanical ventilation, the use of i-lung is designed to avoid sedation and immobility, thus creating active, self-managed patients," said Georg Matheis, MD, Managing Director & Founder of XENIOS. "In addition, i-lung is designed to be used to bridge the waiting time for a donor organ (bridge-to-lung-transplant)."
"Of special note," added Juergen Boehm, MD, Managing Director of Xenios, "i-lung paves the way for XENiOS to continue development of a bioartificial lung for use by patients outside of a hospital environment analogous to current artificial heart protocols, which will represent a paradigm shift in the approach to long-term respiratory support."
i-lung is the result of the successful completion of the AmbuLung project, a three-year R&D consortium project funded by the European Union’s FP7 Program that developed the basis for i-lung, the world’s first-of-its-kind wearable artificial lung. In addition to XENiOS, the consortium included Fraunhofer IGB (Stuttgart, Germany); Imperial College of Science, Technology and Medicine (London, UK); and, the University of Florence (Italy).
"We are forever indebted to the vision and the work of Professor Dame Julia Polak, who passed away last year," said Dr. Matheis. "Julia and I co-founded the i-lung project, and because of her enormous contribution i-lung is now a reality, and a bioartificial next-gen of i-lung on the horizon." The author of some 1,000 original papers, 115 review articles and editor or author of 25 books, Julia Polak, MD, PhD, was one of the most widely cited researchers in her field, and had undergone a heart lung transplant. She served on several national and international tissue engineering and stem cell advisory panels, and was the European editor of the journal Tissue Engineering.
Funding for the commercialization of i-LUNG® has already been procured. XENIOS announced in September 2015 that it received an eight-figures cash infusion from existing investors, in part to fund CE-marking and launch of i-LUNG, led by ZFHN, one of the largest Single Family Offices in Germany investing in start-up companies.
XENiOS AG is a privately held medical technology company that is comprised of two product brands, novalung® and i–cor®, that run on a single XENiOS® console. The XENIOS platform is designed to provide at least four essential advantages with its minimally invasive lung and heart therapies: (1) patients are awake and mobile;(2) self-actuated patients facilitate improved outcomes; (3) there is no ventilator-associated lung injury or pneumonia; (4) additionally, the XENIOS platform maintains a physiologic natural pulse designed to protect the heart.
Most Popular Now
Medelinked is now integrated with Microsoft Health and Band. The integration ensures that wellness summary data from Microsoft Health app and Band wearable is available i...Read more
Following a successful pilot programme to deliver more integrated care to heart failure patients, Torbay and South Devon NHS Foundation Trust is rolling out the InterSyst...Read more
During the 2014 FIFA World Cup opening ceremony, a young Brazilian man, paralyzed from the chest down, delivered the opening kickoff. He used a brain-machine interface, a...Read more
Nervecentre Software has launched a mobile clinical photography solution for nurses and doctors in hospitals. Fully integrated directly into the patient record, the mobil...Read more
The term 'in silico clinical trials' refers to: "The use of individualised computer simulation in the development or regulatory evaluation of a medicinal product, medica...Read more
A commonly used device found in living rooms around the world could be a cheap and effective means of evaluating the walking difficulties of multiple sclerosis (MS) patie...Read more
The combination of augmented reality technology, geocaching, and other novel techniques to create innovative active video games (AVGs) has potential personal and public h...Read more
With over two-thirds of U.S. adults owning a smartphone, and the rise in miniaturized sensors and low-power body area networks that are used for remote health monitoring...Read more
Agfa HealthCare, a leader and innovator in the medical imaging and healthcare IT space, today announced that the U.S. government has awarded the company its DIN-PACS IV (...Read more